Molecular pathways altered by insulin B9-23 immunization

Sarah E. Eckenrode, Qing Guo Ruan, Christin D. Collins, Ping Yang, Richard A McIndoe, Andrew Muir, Jin-Xiong She

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Type 1 diabetes (T1D) in the nonobese diabetic (NOD) mouse can be delayed by administration of insulin or specific insulin peptides. To better understand how insulin treatment delays diabetes development, NOD mice treated with an insulin peptide (B9-23) were compared with age-matched NOD and NOD congenic mice for gene expression changes in spleen using cDNA microarray. Fifty genes were identified that were significantly altered by B9-23 treatment. Thirty-three of these genes are downregulated by the treatment while they are upregulated during the natural disease progression in NOD from immature (3-4 weeks) to mature (10 weeks) stages. Taken together, our data suggest that the B9-23 treatment, like the protective genes in NOD congenic strains, reduces pro-inflammatory activation of lymphocytes that normally occurs in NOD mice. Furthermore, our studies discovered two genes (Irf4 and Tra1) with increased expression in B9-23-treated mice that promote the Th2 response, providing a molecular basis for the B9-23-protective therapy.

Original languageEnglish (US)
Pages (from-to)175-185
Number of pages11
JournalAnnals of the New York Academy of Sciences
Volume1037
DOIs
StatePublished - Jan 1 2004

Fingerprint

Immunization
Inbred NOD Mouse
Genes
Insulin
Medical problems
Lymphocytes
Congenic Mice
Therapeutics
Microarrays
Gene expression
Lymphocyte Activation
Oligonucleotide Array Sequence Analysis
Type 1 Diabetes Mellitus
Complementary DNA
Chemical activation
Disease Progression
Down-Regulation
Spleen
Peptides
Mouse

Keywords

  • B9-23 treatment
  • Insulin
  • Microarray
  • NOD
  • Th1/Th2 balance

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Molecular pathways altered by insulin B9-23 immunization. / Eckenrode, Sarah E.; Ruan, Qing Guo; Collins, Christin D.; Yang, Ping; McIndoe, Richard A; Muir, Andrew; She, Jin-Xiong.

In: Annals of the New York Academy of Sciences, Vol. 1037, 01.01.2004, p. 175-185.

Research output: Contribution to journalArticle

Eckenrode, Sarah E. ; Ruan, Qing Guo ; Collins, Christin D. ; Yang, Ping ; McIndoe, Richard A ; Muir, Andrew ; She, Jin-Xiong. / Molecular pathways altered by insulin B9-23 immunization. In: Annals of the New York Academy of Sciences. 2004 ; Vol. 1037. pp. 175-185.
@article{fbd1f40cda3240a480c2013a3ca25df2,
title = "Molecular pathways altered by insulin B9-23 immunization",
abstract = "Type 1 diabetes (T1D) in the nonobese diabetic (NOD) mouse can be delayed by administration of insulin or specific insulin peptides. To better understand how insulin treatment delays diabetes development, NOD mice treated with an insulin peptide (B9-23) were compared with age-matched NOD and NOD congenic mice for gene expression changes in spleen using cDNA microarray. Fifty genes were identified that were significantly altered by B9-23 treatment. Thirty-three of these genes are downregulated by the treatment while they are upregulated during the natural disease progression in NOD from immature (3-4 weeks) to mature (10 weeks) stages. Taken together, our data suggest that the B9-23 treatment, like the protective genes in NOD congenic strains, reduces pro-inflammatory activation of lymphocytes that normally occurs in NOD mice. Furthermore, our studies discovered two genes (Irf4 and Tra1) with increased expression in B9-23-treated mice that promote the Th2 response, providing a molecular basis for the B9-23-protective therapy.",
keywords = "B9-23 treatment, Insulin, Microarray, NOD, Th1/Th2 balance",
author = "Eckenrode, {Sarah E.} and Ruan, {Qing Guo} and Collins, {Christin D.} and Ping Yang and McIndoe, {Richard A} and Andrew Muir and Jin-Xiong She",
year = "2004",
month = "1",
day = "1",
doi = "10.1196/annals.1337.029",
language = "English (US)",
volume = "1037",
pages = "175--185",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Molecular pathways altered by insulin B9-23 immunization

AU - Eckenrode, Sarah E.

AU - Ruan, Qing Guo

AU - Collins, Christin D.

AU - Yang, Ping

AU - McIndoe, Richard A

AU - Muir, Andrew

AU - She, Jin-Xiong

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Type 1 diabetes (T1D) in the nonobese diabetic (NOD) mouse can be delayed by administration of insulin or specific insulin peptides. To better understand how insulin treatment delays diabetes development, NOD mice treated with an insulin peptide (B9-23) were compared with age-matched NOD and NOD congenic mice for gene expression changes in spleen using cDNA microarray. Fifty genes were identified that were significantly altered by B9-23 treatment. Thirty-three of these genes are downregulated by the treatment while they are upregulated during the natural disease progression in NOD from immature (3-4 weeks) to mature (10 weeks) stages. Taken together, our data suggest that the B9-23 treatment, like the protective genes in NOD congenic strains, reduces pro-inflammatory activation of lymphocytes that normally occurs in NOD mice. Furthermore, our studies discovered two genes (Irf4 and Tra1) with increased expression in B9-23-treated mice that promote the Th2 response, providing a molecular basis for the B9-23-protective therapy.

AB - Type 1 diabetes (T1D) in the nonobese diabetic (NOD) mouse can be delayed by administration of insulin or specific insulin peptides. To better understand how insulin treatment delays diabetes development, NOD mice treated with an insulin peptide (B9-23) were compared with age-matched NOD and NOD congenic mice for gene expression changes in spleen using cDNA microarray. Fifty genes were identified that were significantly altered by B9-23 treatment. Thirty-three of these genes are downregulated by the treatment while they are upregulated during the natural disease progression in NOD from immature (3-4 weeks) to mature (10 weeks) stages. Taken together, our data suggest that the B9-23 treatment, like the protective genes in NOD congenic strains, reduces pro-inflammatory activation of lymphocytes that normally occurs in NOD mice. Furthermore, our studies discovered two genes (Irf4 and Tra1) with increased expression in B9-23-treated mice that promote the Th2 response, providing a molecular basis for the B9-23-protective therapy.

KW - B9-23 treatment

KW - Insulin

KW - Microarray

KW - NOD

KW - Th1/Th2 balance

UR - http://www.scopus.com/inward/record.url?scp=14544294979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544294979&partnerID=8YFLogxK

U2 - 10.1196/annals.1337.029

DO - 10.1196/annals.1337.029

M3 - Article

VL - 1037

SP - 175

EP - 185

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -